“China” or “PRC”

“Companies Ordinance”

“Companies (Winding Up and

Miscellaneous Provisions)
Ordinance”

DEFINITIONS

the People’s Republic of China and for the purposes of this
prospectus only, except where the context requires otherwise,
references to China or the PRC exclude Hong Kong, Macau
and Taiwan

the Companies Ordinance (Chapter 622 of the Laws of Hong
Kong), as amended, supplemented or otherwise modified from
time to time

the Companies (Winding Up and Miscellaneous Provisions)
Ordinance (Chapter 32 of
the Laws of Hong Kong), as
amended, supplemented or otherwise modified from time to
time

“Company”, “our Company”, or

“the Company”

BeiGene, Ltd., an exempted company with limited liability
incorporated under the laws of the Cayman Islands on October
28, 2010

“connected person(s)”

has the meaning ascribed to it under the Listing Rules

“connected transaction(s)”

has the meaning ascribed to it under the Listing Rules

“Core Product Candidates”

“CSRC”

“Director(s)”

“Downward Offer Price

Adjustment”

“EMA”

“Equity Plans”

“Ex-PRC”

“FDA”

Bruton’s
an

zanubrutinib (BGB-3111), an investigational small molecule
inhibitor
tislelizumab
of
(BGB-A317),
humanized monoclonal
antibody against the immune checkpoint receptor PD-1; and
pamiparib (BGB-290), an investigational
small molecule
inhibitor of the PARP1 and PARP2 enzymes

investigational

tyrosine

kinase;

China Securities Regulatory Commission

the director(s) of the Company

an adjustment that has the effect of setting the final Offer
Price up to 10% below the bottom end of the indicative Offer
Price Range

European Medicines Agency

the 2011 Option Plan, the 2016 Share Option and Incentive
Plan, the 2018 ESPP and the 2018 Inducement Equity Plan

worldwide except PRC

U.S. Food and Drug Administration

“Frost & Sullivan”

Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.

“Frost & Sullivan Report”

the industry report in respect of the Global Offering issued by
Frost & Sullivan

— 26 —

